To compare the new macrolide antibiotic clarithromycin with erythromycin in terms of in vitro activity, pharmacokinetics, pharmacodynamics, clinical efficacy, and toxicity.
DATA IDENTIFICATION:
An English-language literature search employing MEDLINE (1987–91), Index Medicus (1987–91), Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (1990), Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (1991), and bibliographic reviews of related textbooks and review articles.
STUDY SELECTION:
Eighty-five articles were selected. Clinical trials with clarithromycin have been limited, and emphasis was placed on trials reported in the Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy and Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy.
DATA EXTRACTION:
Articles were assessed for study quality and specific information addressing the stated purpose. In articles reporting the results of clinical trials, emphasis was placed on comparative efficacy and toxicity.
RESULTS OF DATA ANALYSIS:
A review of 24 human trials suggests that clarithromycin is equally effective as erythromycin, penicillin VK, ampicillin, or amoxicillin for treatment of a variety of upper and lower respiratory tract or skin infections. Clarithromycin also appears to be better tolerated than these agents, with a lower incidence of gastrointestinal adverse effects. Limited clinical studies in patients with Mycobacterium leprae or Mycobacterium aviumintracellulare complex (MAI) suggest that clarithromycin may prove to be efficacious and well tolerated in the treatment of these infections.
CONCLUSIONS:
Clarithromycin is as effective in vivo as erythromycin, with less gastrointestinal irritation. Additionally, clarithromycin appears to expand the traditional spectrum of macrolide antibiotics, with promising activity against M. leprae and MAI.
Get full access to this article
View all access options for this article.
References
1.
NeuHC. The development of macrolides: Clarithromycin in perspective. J Antimicrob Chemother1991; 27 (suppl A):1–9.
2.
WashingtonJEWilsonWR. Erythromycin: A microbiological and clinical perspective after 30 years of clinical use. Mayo Clin Proc1985; 60: 189–203.
3.
FernandesPB. The macrolide revival: Thirty years after erythromycin. Antimicrob News1987; 4 (4):25–34.
4.
HoppeJEEichhornA. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. Eur J Microbiol Infect Dis1989; 8: 653–4.
5.
MorimotoSTakahashiYWatanabeYOmuraS. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-memylerythromycins A. J Antibiot1984; 37: 187–9.
6.
KurathPJonesPHEganRSPerunTJ. Acid degradation of erythromycin A and erythromycin B. Experientia1971; 27: 362.
7.
OmuraSTsuzukiKSunazukaTMaruiSToyodaH. Macrolides with gastrointestinal motor stimulating activity. J Med Chem1987; 30: 1941–3.
8.
ItohZSuzukiTNakayaMInoueMMitsuhashiS. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother1984; 26: 863–9.
9.
ItohZSuzukiTNakayaMInoueMAraiHWakabayashiK. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol1985; 11: G320–5.
10.
AndersonRJooneGvan RensburgEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother1988; 22: 923–33.
11.
PestkaS. Inhibitors of protein synthesis. In: WeissbachHPestkaS, eds. Molecular mechanisms of protein biosynthesis. New York: Academic Press, 1977: 467.
12.
OleinickNL. The erythromycins. In: CorcoranJWHahnFE, eds. Mechanism of action of antimicrobial and antitumor agents. New York: Springer-Verlag, 1975: 396.
13.
FranklinTJSnowGA. Biochemistry of antimicrobial action. 3rd ed.London: Chapman and Hall, 1981: 128.
14.
GaleEFCundliffeECReynoldsPERichmondMHWaringMJ, eds. In: The molecular basis of antibiotic action. 2nd ed.London: Wiley Interscience, 1972: 484–8.
15.
DubnauD. Translational attenuation: The regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. CRC Crit Rev Biochem1986; 16: 103–31.
16.
WeisblumB. Inducible erythromycin resistance in bacteria. Br Med Bull1984; 40: 47–53.
17.
FernandesPBBakerWRFreibergLAHardyDJMcDonaldEJ. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob Agents Chemother1989; 33: 78–81.
18.
Thakker-VariaSJenssenWDMoon-McDermottLWeinsteinMPDubinDT. Molecular epidemiology of macrolides-lincosamides-streptogramin B resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother1987; 31: 735–43.
19.
FosterTJ. Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria. Microbiol Rev1983; 47: 361–409.
20.
HoriouchiSWeisblumB. Posttranscriptional modification of mRNA confirmation: Mechanism that regulates erythromycin-induced resistance. Proc Nat Acad Sci U S A1980; 77: 7079–83.
21.
FernandesPBBailerRSwansonRHansonCWMcDonaldERamerNIn vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother1986; 30: 865–73.
22.
FernandesPBHardyDJ. Comparative in vitro potencies of nine new macrolides. Drugs Exp Clin Res1988; 14: 445–51.
23.
HardyDJSwansonRNRodeRAMarshKShipkowitzNLClementJJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother1990; 34: 1407–13.
24.
RoszkowskiKBeuthJKoHLPetersGPulvererG. Comparative study on the macrolides erythromycin and clarithromycin: Antibacterial activity and influence on immune responses. Zbl Bakt1990; 273: 518–30.
25.
HardyDJHenseyDMBeyerJMVojtkoCMcDonaldEJFernandesPB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother1988; 32: 1710–9.
26.
AndrewsJMAshbyJPWiseR. Factors affecting the in vitro activity of roxithromycin. J Antimicrob Chemother1987; 20 (suppl B):31.
27.
Olsson-LiljequistBHoffmanBM. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae. J Antimicrob Chemother1991; 27 (suppl A):11–7.
28.
DabernatHDelmasCSeguyMFourtillanJBGiraultJLarengMB. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal rests. J Antimicrob Chemother1991; 27 (suppl A):19–30.
29.
HardyDJSwansonRNRodeRAMarshKShipkowitzNLClementJJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother1990; 34: 1407–13.
30.
ValleeEAzoulay-DupuisESwansonRBergogne-BerezinEPocidaloJJ. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J Antimicrob Chemother1991; 27 (suppl A):31–41.
31.
FernandesPBFreibergLA. Antibacterial activity of N-demethyl and 14-OH metabolites of A-56268 (TE-031) (abstract 408). In: Program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1986.
32.
LoganMNAshbyJPAndrewsJM. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite. J Antimicrob Chemother1991; 27: 161–70.
33.
FranzblauSGHastingsRC. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother1988; 32: 1758–62.
34.
NaikSRuckR. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother1989; 33: 1614–6.
35.
InderliedCBSandovalFGYoungLS. In vitro activity of clarithromycin (CLARI) and 14-hydroxy-clarithromycin against the Mycobacterium avium complex (MAC) alone and in combination with other agents (abstract 239). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
36.
BrownSTEdwardsFFBernardEMArmstrongD. Inhibition of Mycobacterium avium complex (MAC) by single agents and combinations (abstract 674). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
37.
HeifetsLBLindholm-LevyPJ. Clarithromycin and temafloxacin: combination effects with other agents against M. avium in vitro (abstract 676). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
38.
EasmonCSF. The effect of antibiotics on the intracellular survival of Staphylococcus aureus in vitro. Br J Exp Pathol1979; 60: 24–8.
39.
MandellGLVestTK. Killing of intraleukocytic Staphylococcus aureus by rifampin: In-vitro and in-vivo studies. J Infect Dis1972; 125: 486–90.
40.
PesantiEL. Protection of staphylococci ingested by macrophages from the bactericidal action of rifampin. Antimicrob Agents Chemother1980; 18: 208–9.
41.
HorwitzMASilversteinSC. Legionnaires' disease bacterium (Legionella pneumophilia) multiplies intracellularly in human monocytes. J Clin Invest1980; 66: 441–50.
42.
VosbeckKJamesPRZimmermanW. Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria. Antimicrob Agents Chemother1984; 25: 735–41.
43.
KirstHASidesG. New directions for macrolide antibiotics: Pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother1989; 33: 1419–22.
44.
AndersonRVan RensburgCEJJooneGLukeyPT. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J Antimicrob Chemother1987; 20 (suppl B):57–68.
45.
DetteGAKnotheH. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leukocytes. J Antimicrob Chemother1986; 18: 73–82.
ProkeschRCHandWL. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother1982; 21: 373–80.
48.
RaghoebarMLindeyerEVan Den BergWBCeesAMGinnekenV. On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leukocytes. Biochem Pharmacol1988; 37: 3221–7.
49.
IshiguroMKogaHKohnoSHayashiTYamaguchiKHirotaM. Penetration of macrolides into human polymorphonuclear leukocytes. J Antimicrob Chemother1989; 24: 719–29.
50.
AndersonRJooneGVan RensburgCEJ. An in vitro investigation of the intracellular bioactivity of amoxicillin, clindamycin, and erythromycin for Staphylococcus aureus. J Infect Dis1986; 153: 593–600.
51.
HorwitzMASilversteinSC. Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophilia) in human monocytes is reversibly inhibited by erythromycin and rifampin. J Clin Invest1983; 71: 15–26.
52.
TakeshitaKYamagishiIHaradaMOtomoSNakagawaTMizushimaY. Immunological and anti-inflammatory effects of clarithromycin: Inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res1989; 15: 527–33.
53.
FerreroJLBoppBAMarshKCQuigleySCJohnsonMJAndersonDJMetabolism and disposition of clarithromycin in man. Drug Metab Dis1990; 18: 441–6.
54.
Package insert. Biaxin (clarithromycin). Chicago, IL: Abbott Laboratories, November 1991.
55.
KohnoYOhtaKSuwaTSugaT. Autobacteriographic studies of clarithromycin and erythromycin in mice. Antimicrob Agents Chemother1990; 34: 562–7.
56.
KohnoYYoshidaHSuwaTSugaT. Uptake of clarithromycin by rat lung cells. J Antimicrob Chemother1990; 26: 503–13.
57.
FraschiniFScaglioneFPintucciGMaccArinelliGDugnaniSDemartiniG. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother1991; 27 (suppl A):61–5.
58.
FraschiniFScaglioneFPintucciJPCogoRTassiGF. Clarithromycin and its 14-OH-metabolite. Pharmacokinetics and tissue distribution in humans (abstract 512). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
59.
AdachiTSasakiJOmuraS. Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by mucor circinelloides. J Antibiot1989; 17: 1433–7.
60.
AdachiTMorimotoSKondohHNagateTWatanabeYSotaK. Fourteen-hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. J Antibiot1988; 16: 966–75.
61.
ChuSYSennelloLTBunnellST. Pharmacokinetics of clarithromycin in subjects with varying renal function (abstract 514). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
62.
O'NeillSJMillarEDColesSJBachandRT. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Ir Med J1991; 84: 33–5.
63.
ScaglioneF. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. Curr Med Res Opin1990; 12: 25–33.
64.
BachandRT. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. J Antimicrob Chemother1991; 27 (suppl A):75–82.
65.
LevensteinJH. Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. J Antimicrob Chemother1991; 27 (suppl A):67–74.
66.
MarchiE. Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. Curr Med Res Opin1990; 12: 19–24.
67.
KarmaPPukanderJPenttilaMYlikoskiJSavolainenSOlenLThe comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother1991; 27 (suppl A):83–90.
68.
BachandR. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother1991; 27 (suppl A):91–100.
69.
AndersonGEsmondeTSColesSMacKlinJCarnegieC. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother1991; 27 (suppl A):117–24.
70.
ChienSMPichottaPSiepmanNChanCK. Treatment of community acquired pneumonia: a randomized controlled trial comparing clarithromycin (CM) and erythromycin (ER) (abstract 872). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
71.
NorthcuttVJCraftJCPichottaP. Safety and efficacy of clarithromycin (C) compared to erythromycin (E) in the treatment (tx) of bacterial skin or skin structure infections (SSSIs) (abstract 1339). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
72.
MillikanLColemanEBoppBNorthcuttVJ. Safety and efficacy of clarithromycin (C) compared to cefadroxil (CEF) in the treatment of mild to moderate bacterial skin or skin structure infections (SSSIs) (abstract 1340). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
73.
KlemensSPDestefanoMSCynamonMH. Clarithromycin in combination with other agents against M. avium complex (MAC) in beige mice (abstract 292). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
74.
Lindholm-LevyPJ. Clarithromycin and temafloxacin: combination effects with other agents against M. avium in vitro (abstract 676). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
75.
DautzenbergBTruffotCLegrisSMeyohasMBerlieHCMercatAActivity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis1991; 144: 564–9.
76.
Saint-MarcTTouraineJL. Clinical experience with a combination of clarithromycin and clofaximine in the treatment of disseminated M. avium infections in AIDS (abstract 237). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
77.
DautzenbergBSaint-MarcTAverousVRoutkovky-NorvalCBreuxJPKristetterMClarithromycin-containing regimens in the treatment of 54 AIDS patients with disseminated Mycobacterium avium-interacellulare infection (abstract 293). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
78.
JametPJiBBobinPGrossetJH. Powerful bactericidal activities of clarithromycin and/or minocycline against M. leprae in man (abstract 970). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
79.
PolisMAHaneiwichSKovacsJADaveyRTWalkerREFalloonJDose escalation study to determine the safety, maximally tolerated dose (MTD), and pharmacokinetics of clarithromycin (clari) with zidovudine (zdv) in HIV-infected persons (abstract 238). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
80.
DananGDescatoireVPessayreD. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther1981; 218: 509–14.
81.
BabanyGLarreyDPessayreD. Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man. In: GibsonGG, ed. Progress in drug metabolism. London: Taylor and Francis, 1988: 61–98.
82.
TinelMDescatoireVLarreyDLoeperJLabbeGLetteronPEffects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther1989; 250: 746–51.
83.
RichensAChuSYSennelloLTSondersRC. Effect of multiple doses of clarithromycin (C) on the pharmacokinetics (pks) of carbamazepine (Carb) (abstract 760). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
84.
RuffFChuSYSondersRCSennelloLT. Effect of multiple doses of clarithromycin (C) on the pharmacokinetics (pks) of theophylline (T) (abstract 761). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
85.
JanouskySNorthcuttVJCraftJC. Comparative safety and efficacy of clarithromycin and reference suspensions in the treatment of children with mild to moderate skin or skin structure infections (abstract 870). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
86.
JanouskySNorthcuttVJCraftJC. Comparative safety and efficacy of clarithromycin and penicillin V suspensions in the treatment of children with streptococcal pharyngitis (abstract 871). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1991.
